Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EBT (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed EBT for 15 consecutive years, with $9.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 68.99% to $9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.5 million through Dec 2025, down 58.84% year-over-year, with the annual reading at $66.5 million for FY2025, 58.84% down from the prior year.
  • EBT hit $9.9 million in Q4 2025 for Corcept Therapeutics, down from $15.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $52.9 million in Q3 2024 to a low of $9.6 million in Q1 2025.
  • Historically, EBT has averaged $29.7 million across 5 years, with a median of $32.1 million in 2021.
  • Biggest five-year swings in EBT: soared 89.83% in 2024 and later plummeted 72.51% in 2025.
  • Year by year, EBT stood at $36.7 million in 2021, then tumbled by 33.92% to $24.3 million in 2022, then surged by 51.63% to $36.8 million in 2023, then dropped by 13.17% to $32.0 million in 2024, then tumbled by 68.99% to $9.9 million in 2025.
  • Business Quant data shows EBT for CORT at $9.9 million in Q4 2025, $15.2 million in Q3 2025, and $31.7 million in Q2 2025.